174 related articles for article (PubMed ID: 34929517)
21. Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors.
Jung JE; Jang Y; Jeong HJ; Kim SJ; Park K; Oh DH; Yu A; Park CS; Han SJ
Bioorg Med Chem Lett; 2022 Nov; 75():128947. PubMed ID: 35995398
[TBL] [Abstract][Full Text] [Related]
22. Development of a High-Throughput Assay to Identify Inhibitors of ENPP1.
Kumar M; Lowery RG
SLAS Discov; 2021 Jun; 26(5):740-746. PubMed ID: 33402044
[TBL] [Abstract][Full Text] [Related]
23. Crystal structures of human ENPP1 in apo and bound forms.
Dennis ML; Newman J; Dolezal O; Hattarki M; Surjadi RN; Nuttall SD; Pham T; Nebl T; Camerino M; Khoo PS; Monahan BJ; Peat TS
Acta Crystallogr D Struct Biol; 2020 Sep; 76(Pt 9):889-898. PubMed ID: 32876064
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, biological evaluation, and docking studies of new raloxifene sulfonate or sulfamate derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase.
El-Gamal MI; Ullah S; Zaraei SO; Jalil S; Zaib S; Zaher DM; Omar HA; Anbar HS; Pelletier J; Sévigny J; Iqbal J
Eur J Med Chem; 2019 Nov; 181():111560. PubMed ID: 31382118
[TBL] [Abstract][Full Text] [Related]
25. Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Biochem Pharmacol; 2024 Feb; 220():116006. PubMed ID: 38142838
[TBL] [Abstract][Full Text] [Related]
26. Insight into small-molecule inhibitors targeting extracellular nucleotide pyrophosphatase/phosphodiesterase1 for potential multiple human diseases.
Du B; Ru J; Zhan Z; Lin C; Liu Y; Mao W; Zhang J
Eur J Med Chem; 2024 Mar; 268():116286. PubMed ID: 38432057
[TBL] [Abstract][Full Text] [Related]
27. Development of cGAMP-Luc, a sensitive and precise coupled enzyme assay to measure cGAMP in complex biological samples.
Mardjuki RE; Carozza JA; Li L
J Biol Chem; 2020 Apr; 295(15):4881-4892. PubMed ID: 32127400
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5'-nucleotidase, and alkaline phosphatase inhibitors.
al-Rashida M; Iqbal J
Med Res Rev; 2014 Jul; 34(4):703-43. PubMed ID: 24115166
[TBL] [Abstract][Full Text] [Related]
29. Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1).
Chang L; Lee SY; Leonczak P; Rozenski J; De Jonghe S; Hanck T; Müller CE; Herdewijn P
J Med Chem; 2014 Dec; 57(23):10080-100. PubMed ID: 25372276
[TBL] [Abstract][Full Text] [Related]
30. Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
Zelikman V; Pelletier J; Simhaev L; Sela A; Gendron FP; Arguin G; Senderowitz H; Sévigny J; Fischer B
J Med Chem; 2018 May; 61(9):3939-3951. PubMed ID: 29681152
[TBL] [Abstract][Full Text] [Related]
31. Probing the high potency of pyrazolyl pyrimidinetriones and thioxopyrimidinediones as selective and efficient non-nucleotide inhibitors of recombinant human ectonucleotidases.
Andleeb H; Hameed S; Ejaz SA; Khan I; Zaib S; Lecka J; Sévigny J; Iqbal J
Bioorg Chem; 2019 Jul; 88():102893. PubMed ID: 30986550
[TBL] [Abstract][Full Text] [Related]
32. Exploration of carboxy pyrazole derivatives: Synthesis, alkaline phosphatase, nucleotide pyrophosphatase/phosphodiesterase and nucleoside triphosphate diphosphohydrolase inhibition studies with potential anticancer profile.
Channar PA; Afzal S; Ejaz SA; Saeed A; Larik FA; Mahesar PA; Lecka J; Sévigny J; Erben MF; Iqbal J
Eur J Med Chem; 2018 Aug; 156():461-478. PubMed ID: 30015078
[TBL] [Abstract][Full Text] [Related]
33. The discovery of potent small molecule cyclic urea activators of STING.
Basu S; Middya S; Banerjee M; Ghosh R; Pryde DC; Yadav DB; Shrivastava R; Surya A
Eur J Med Chem; 2022 Feb; 229():114087. PubMed ID: 34998056
[TBL] [Abstract][Full Text] [Related]
34. A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.
Wu Y; Zhang Y; Chen X; Hu Y; Dong G; Guo Y; Sheng C
Eur J Med Chem; 2021 Mar; 213():113163. PubMed ID: 33482599
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
Bravo Y; Teriete P; Dhanya RP; Dahl R; Lee PS; Kiffer-Moreira T; Ganji SR; Sergienko E; Smith LH; Farquharson C; Millán JL; Cosford ND
Bioorg Med Chem Lett; 2014 Sep; 24(17):4308-11. PubMed ID: 25124115
[TBL] [Abstract][Full Text] [Related]
36. Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D.
Goyal S; Patel KV; Nagare Y; Raykar DB; Raikar SS; Dolas A; Khurana P; Cyriac R; Sarak S; Gangar M; Agarwal AK; Kulkarni A
Bioorg Med Chem; 2021 Jan; 29():115879. PubMed ID: 33271453
[TBL] [Abstract][Full Text] [Related]
37. Nonhydrolyzable ATP analogues as selective inhibitors of human NPP1: a combined computational/experimental study.
Lecka J; Ben-David G; Simhaev L; Eliahu S; Oscar J; Luyindula P; Pelletier J; Fischer B; Senderowitz H; Sévigny J
J Med Chem; 2013 Nov; 56(21):8308-20. PubMed ID: 24083941
[TBL] [Abstract][Full Text] [Related]
38. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship study of NPP1 inhibitors based on uracil-N1-(methoxy)ethyl-β-phosphate scaffold.
Nassir M; Pelletier J; Arad U; Arguin G; Khazanov N; Gendron FP; Sévigny J; Senderowitz H; Fischer B
Eur J Med Chem; 2019 Dec; 184():111754. PubMed ID: 31610377
[TBL] [Abstract][Full Text] [Related]
40. A fragment-like approach to PYCR1 inhibition.
Milne K; Sun J; Zaal EA; Mowat J; Celie PHN; Fish A; Berkers CR; Forlani G; Loayza-Puch F; Jamieson C; Agami R
Bioorg Med Chem Lett; 2019 Sep; 29(18):2626-2631. PubMed ID: 31362921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
